Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Chlorozotocin was administered by rapid intravenous infusion to 35 patients with advanced cancer on either single-day of five-consecutive-day schedules. Total doses per course ranged from 12.5 to 200 mg/m2. On either administration schedule, dose limiting toxicities were thrombocytopenia and leukopenia at total doses of 150 mg/m2 to 200 mg/m2. Repetitive courses of drug may produce progressive impairment of renal and bone marrow function. Nausea and vomiting were infrequent and mild without definite relationship to dose. Minor reversible nondose related increases in SGOT and in serum creatinine occurred at all doses on both schedules. The plasma half-life of intact N-nitroso groups averaged 9.5 minutes after rapid intravenous administration of doses up to 40 mg/m2 and 12.5 minutes after doses of 150 or 200 mg/m2. No differences between plasma half-lives were seen between identical doses given on the first and fifth days of the five-day schedule. Objective tumor regression was noted in one patient with bronchogenic large cell carcinoma and one patient with metastatic melanoma.
 ...
PMID:A phase I study of chlorozotocin (NSC 178248). 15 80

We report new operative approaches to the treatment of hepatic vein occlusion due to malignant tumors in the liver and their results in four patients. Two patients had hepatoma, one had metastatic melanoma, and one had metastatic leiomyosarcoma. All of them had abdominal pain, abdominal distention secondary to ascites, and massive hepatomegaly. The right lobe and medial segment of the left lobe of the liver were involved in three patients, and the involvement was diffuse throughout the liver in one. Hepatic veins were occluded completely in one patient, and two of three veins were occluded in the others. Two patients were treated by hepatic resection and removal of tumor thrombus from the hepatic vein under isolation-perfusion technique. They lived 18 and six months, respectively, without recurrence of Budd-Chiari syndrome. Tumors in the other patients were diffuse and could not be resected. The hepatic artery was ligated and chemotherapy was given postoperatively. Ascites and abdominal pain disappeared completely in one, who survived 17 months. The other patient had significant palliation and lived nine months.
 ...
PMID:Surgical management of hepatic vein occlusion by tumor: Budd-Chiari syndrome. 19 61

Human melanoma cells, freshly obtained from nine primary and metastatic melanoma cases, were tested for binding of monoclonal anti-melanoma antibodies produced in vitro by hybridoma clones. Monoclonal anti-melanoma antibodies bind to melanoma cells but do not react with nonmalignant cells obtained from the same patients or with cells obtained from giant hairy nevus. These results confirm the existence of tumor-specific antigens. Binding of monoclonal antibodies to melanoma cells of several origins, primary or metastatic, from different patients suggests the existence of tumor antigens shared by human melanoma cells. The binding pattern of different antibodies to various cells also predicts the existence of more than one tumor-specific antigenic determinant on melanoma cells.
 ...
PMID:Reactivity of monoclonal anti-melanoma antibodies with melanoma cells freshly isolated from primary and metastatic melanoma. 37 94

Complete follow-up information was obtained on 65 patients whose eyes had been enucleated for small choroidal melanomas three months to 34 years previously. All tumors were 300 cu mm (10 x 10 x 3 mm) or less in volume. The average and median lengths of follow-up were nine years and 7.2 years, respectively. The 5-, 10-, and 15-year tumor-related death rates were found to be lower than those previously reported for small melanomas after enucleation, and the same as the estimated tumor-related mortality in patients who had not undergone enucleation. The average volume of tumors that caused metastatic death was more than twice that of tumors that did not. There were no metastatic deaths in 42 patients with tumors less than 98 cu mm (7 x 7 x 2 mm) in volume. Waiting to observe growth in tumors less than 98 cu mm in size did not appear to increase the risk of death from metastatic melanoma.
 ...
PMID:Small choroidal melanomas. A long-term follow-up study. 44 17

Two cases of cystic metastatic melanoma are presented. The only reliable computed tomography sign of a true cystic lesion is the presence of an interface, such as between blood and tumor fluid. Differentiation of cystic metastatic melanoma from other cystic lesions of the brain is discussed.
 ...
PMID:Fluid--fluid level in cystic cerebral metastatic melanoma. 47 17

A patient with metastatic melanoma developed symmetric miliary infiltrates of the lungs while receiving injections of MER into tumor containing lymph nodes of the groin. Open lung biopsy identified the pulmonary lesions as caseating epithelioid granulomas. After cessation of MER therapy, the pulmonary lesions regressed spontaneously. The possible etiology of this so-far-unreported complication of MER therapy was briefly discussed.
 ...
PMID:Pulmonary granulomas in a patient on MER therapy. 61 59

Twenty one patients with advanced metastatic melanoma were treated with a combination of 1-methyl-1-nitrosourea (MNU) and cyclophosphamide. All the patients had not previously been treated with cytostatics. MNU in the dose of 4 mg/kg and cyclophosphamide in the dose of 8 mg/kg body weight was administered daily. The drugs were given in 6 day cycles. Objective response (greater than 50% tumor regression) was obtained in 8 (38%) of the 21 treated patients, with 2 complete and 6 partial remissions. The duration of remission was 2--12 months (M = 6.2 months). Injections of MNU caused nausea and vomiting in approximately all the treated patients. Combination of these drugs, however, produced myelodepression in 33% of treated patients. This combination of drugs showed antitumor activity in metastatic malignant melanoma, particularly in melanoma metastasis of the lung, brain and lymph nodes and needs further investigation.
 ...
PMID:Combination chemotherapy with 1-methyl-1-nitrosourea and cyclophosphamide in metastatic melanoma. 65 33

Human fibroblast interferon (HFIF) produced on a large scale from normal diploid cell strains was highly purified and then evaluated as to its safety clinical investigation. The selective antiproliferative activity of HFIF was observed in vitro against certain human malignant cell lines and in vivo against human bladder tumors grown in nude mice. Direct injections of HFIF into metastatic melanoma lesions of two patients resulted in either the disappearance of malignant cells or the significant reduction in tumor volume.
 ...
PMID:Human fibroblast interferon in human neoplasia: clinical and laboratory study. 72 9

The clinical and echocardiographic findings of four patients with right ventricular tumors (three myxomas and one metastatic melanoma) are presented. All four patients previously had been evaluated by competent cardiologists, and the diagnosis of a right ventricular tumor was missed. The initial echocardiograms were interpreted as not showing any right ventricular tumor; but on review we found that the correct diagnosis could have been made. The presence of the right ventricular myxomas was confirmed at angiography and surgery. However, the attachment of the stalk of the mycoma could not be determined confidently by angiography alone, and in two of the three cases two-dimensional echocardiography was required to identify correctly the location of the base of the stalk. This paper emphasizes the usefulness and technical difficulties of M-mode and two-dimensional echocardiography in the diagnosis of a right ventricular tumor.
 ...
PMID:Echocardiography of right ventricular tumors. 88 99

The hypothesis that abnormalities in intercellular adhesion are a property of metastatic tumors was examined in vitro with B16 melanoma variants that were selected in vivo for increased metastatic behavior. The adhesive characteristics of low (B16-F1), intermediate (B16-F5), and high (B16-F10) metastatic lines were determined by quantitative adhesion assays that measured the rate and degree of attachment of single cells to confluent monolayers of melanoma, BALB/3T3, or virus-transformed 3T3 cells. Intercellular adhesions were monitored by loss of single cells from suspension and adherence of intraperitoneally grown 125I-5-iodo-2'-deoxyuridine-labeled cells to the monolayers, and were affected by time, temperature, and serum concentration. Although there was little difference in adhesive properties between the untransformed and transformed 3T3 cell lines, the more metastatic melanoma variants exhibited higher relative rates and extents of homotypic and heterotypic monolayer attachment compared with lower metastatic lines (B16-F10 greater than B16-F5 greater than B16-F1). The correlation between in vivo and in vitro tumor cell adhesive properties and metastasis was discussed.
 ...
PMID:Determination of adhesive properties of variant metastatic melanoma cells to BALB/3T3 cells and their virus-transformed derivatives by a monolayer attachment assay. 94 56


1 2 3 4 5 6 7 8 9 10 Next >>